Pharmacological characterization of the selective, orally bioavailable, potent mTORC1/2 inhibitor PQR620

被引：0
|
作者：
Beaufils, Florent
Rageot, Denise
Melone, Anna
Sele, Alexander
Lang, Marc
Mestan, Juergen
Ettlin, Robert A.
Hillmann, Petra
Cmiljanovic, Vladimir
Walter, Carolin
Singer, Elisabeth
Nguyen, Hoa H. P.
Hebeisen, Paul
Fabbro, Dorian
Wymann, Matthias P.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-393A
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
393A
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor
    Zheng, Xiufang
    Gao, Lu
    Wang, Lisha
    Liang, Chungen
    Wang, Baoxia
    Liu, Yongfu
    Feng, Song
    Zhang, Bo
    Zhou, Mingwei
    Yu, Xin
    Xiang, Kunlun
    Chen, Li
    Guo, Tao
    Shen, Hong C.
    Zou, Gang
    Wu, Jim Zhen
    Yun, Hongying
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (13) : 6003 - 6014
  • [42] The discovery of YM-60828: A potent, selective and orally-bioavailable Factor Xa inhibitor
    Hirayama, F
    Koshio, H
    Katayama, N
    Kurihara, H
    Taniuchi, Y
    Sato, K
    Hisamichi, N
    Sakai-Moritani, Y
    Kawasaki, T
    Matsumoto, Y
    Yanagisawa, I
    BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (05) : 1509 - 1523
  • [43] Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
    Johnson, Douglas S.
    Stiff, Cory
    Lazerwith, Scott E.
    Kesten, Suzanne R.
    Fay, Lorraine K.
    Morris, Mark
    Beidler, David
    Liimatta, Marya B.
    Smith, Sarah E.
    Dudley, David T.
    Sadagopan, Nalini
    Bhattachar, Shobha N.
    Kesten, Stephen J.
    Nomanbhoy, Tyzoon K.
    Cravatt, Benjamin F.
    Ahn, Kay
    ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (02): : 91 - 96
  • [44] Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor
    Ito, Toshiya
    Kinoshita, Kazutomo
    Tomizawa, Masaki
    Shinohara, Shojiro
    Nishii, Hiroki
    Matsushita, Masayuki
    Hattori, Kazuo
    Kohchi, Yasunori
    Kohchi, Masami
    Hayase, Tadakatsu
    Watanabe, Fumio
    Hasegawa, Kiyoshi
    Tanaka, Hiroshi
    Kuramoto, Shino
    Takanashi, Kenji
    Oikawa, Nobuhiro
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (18) : 12427 - 12444
  • [45] In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor.
    Luettgen, Joseph M.
    Bozarth, Tracy A.
    Bozarth, Jeffrey M.
    Barbera, Frank A.
    Lam, Patrick Y.
    Quan, Mimi L.
    Pinto, Donald J.
    Wexler, Ruth R.
    Rendina, Alan R.
    Knabb, Robert M.
    BLOOD, 2006, 108 (11) : 112B - 112B
  • [46] Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor
    Yu, Tao
    Zhang, Yonglian
    Kerekes, Angela D.
    Tagat, Jayaram R.
    Doll, Ronald J.
    Xiao, Yushi
    Esposite, Sara
    Hruza, Alan
    Belanger, David B.
    Voss, Matthew
    Rainka, Matthew P.
    Basso, Andrea
    Liu, Ming
    Liang, Lianzhu
    Sui, Ning
    Prelusky, Daniel
    Rindgen, Diane
    Zhang, Likang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (08) : 1397 - 1403
  • [47] Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor
    Iyer, Chandrasekar
    Li, Binghui
    Stewart, Trent R.
    Wang, Tao
    Capen, Andrew
    Cavitt, Rachel
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Zhao, Gaiying
    Rodriguez, Michael J.
    Carballares, Santiago
    Cooke, Andrew
    Bondi, Robert
    Burns, Lee
    Kelamangalath, Lakshmi
    Wallace, Ross
    Kolakowski, Gabrielle
    Henry, James R.
    Si, Chong
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [48] Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist
    Baska, Ferenc
    Bozo, Eva
    Szeleczky, Zsolt
    Szanto, Gabor
    Vukics, Krisztina
    Szakacs, Zoltan
    Domany-Kovacs, Katalin
    Kurko, Dalma
    Vass, Elemer
    Than, Marta
    Vastag, Monika
    Temesvari, Krisztina
    Levai, Sandor
    Halasz, Attila Sandor
    Kordas, Krisztina Szondine
    Roman, Viktor
    Greiner, Istvan
    Bata, Imre
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (01) : 643 - 673
  • [49] Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2
    Crew, Andrew P.
    Bhagwat, Shripad V.
    Dong, Hanqing
    Bittner, Mark A.
    Chan, Anna
    Chen, Xin
    Coate, Heather
    Cooke, Andrew
    Gokhale, Prafulla C.
    Honda, Ayako
    Jin, Meizhong
    Kahler, Jennifer
    Mantis, Christine
    Mulvihill, Mark J.
    Tavares-Greco, Paula A.
    Volk, Brian
    Wang, Jing
    Werner, Douglas S.
    Arnold, Lee D.
    Pachter, Jonathan A.
    Wild, Robert
    Gibson, Neil W.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (07) : 2092 - 2097
  • [50] In Vitro and In Vivo Pharmacological Profiles of DS-1211, a Novel Potent, Selective, and Orally Bioavailable Tissue-Nonspecific Alkaline Phosphatase Inhibitor
    Soma, Kaori
    Izumi, Masanori
    Yamamoto, Yuko
    Miyazaki, Shojiro
    Watanabe, Kengo
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (10) : 2033 - 2043
12345